Roivant Sciences Ltd. (ROIV)

Guru Stock PicksPaul Singer has made the following transactions:Reduce in LUV by 8.86%Stock News Meta taps AMD for AI buildout: Meta Platforms (META) signed a m

Stock News Dimon warns on credit cycle: JPMorgan Chase (JPM) CEO Jamie Dimon cautioned that elevated asset prices and growing banking competition echo pre‑200

Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction on Friday, February 13th. The stock was sold at an average price of $26.49, for a total value of $5,298,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,654,597 shares

Jefferies Group (Trades, Portfolio)'s Strategic Moves in Q4 2025: A Detailed Analysis Jefferies Group (Trades, Portfolio) recently submitted its 13F filing for

New York State Common Retirement Fund lifted its stake in shares of Roivant Sciences Ltd. (NASDAQ: ROIV) by 25.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 229,037 shares of the company's stock after acquiring an additional 46,344 shares during the

Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report)'s stock price hit a new 52-week high on Friday. The stock traded as high as $25.49 and last traded at $24.7320, with a volume of 3598048 shares. The stock had previously closed at $21.14. Key Headlines Impacting Roivant Sciences Here are the key news stories impacting

Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade)

Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.27.

BASEL, Switzerland and LONDON and NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reported its financial results for the third quarter ended December 31, 2025.

DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced positive results from the Phase 2 BEACON study evaluating brepocitinib in cutaneous sarcoidosis (CS). CS is a highly morbid, chronic, and disfiguring condition with no approved therapies, and the BEACON study is the first ever industry-sponsored placebo-controlled trial in the indication to read out positively.

WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that it has completed enrollment in the Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients.

BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, and provide a business update.

Campbell and CO Investment Adviser LLC trimmed its holdings in Roivant Sciences Ltd. (NASDAQ: ROIV) by 65.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,753 shares of the company's stock after selling 68,705 shares during the period. Campbell and CO

Roivant Sciences (NASDAQ: ROIV - Get Free Report) and NovAccess Global (OTCMKTS:XSNX - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Analyst Recommendations This is a breakdown of current

Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.